Bill > HF2624

This bill modifies Minnesota's prescription monitoring program by changing the terminology from "controlled substances" to "reportable substances," which now explicitly includes butalbital, gabapentin, and FDA-approved opioid overdose reversal agents (opioid antagonists). The bill updates various sections of the state's prescription monitoring program statutes to reflect this new terminology, expanding the scope of substances tracked in the electronic reporting system. The legislation maintains the existing requirements for dispensers to report prescription data to the Board of Pharmacy, including details such as patient information, prescription details, and dispensing information. The bill also preserves existing provisions about who can access the prescription monitoring database, including healthcare providers, pharmacists, and certain authorized personnel, while adding a specific restriction that access to data on opioid antagonists is limited to board personnel engaged in program administration and maintenance. Additionally, the bill continues to emphasize patient privacy, requiring data to be maintained in an encrypted form and destroyed within 12 months, with provisions for de-identified data to be retained for analysis purposes. The changes aim to improve tracking of potentially dangerous or misused substances while maintaining patient confidentiality and supporting appropriate medical care.

Health and Social Services

https://www.revisor.mn.gov/bills/bill.php?b=House&f=HF2624&ssn=0&y=2025